ClinicalTrials.gg

Program

abdenoflast

A development code. Also written as “VTX2735”.

Its studies are mostly in Pericarditis · Cryopyrin-Associated Periodic Syndromes, led by Eli Lilly.

Furthest: phase 2, since Mar 28, 20232 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly21 open or runningphase 2since Mar 28, 2023Mar 28, 2023Oct 2027phase 2 · NCT06836232
  • Named in Eli Lilly’s own pipeline as Abdenoflast (VTX2735), phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2023First study: phase 2 study in Cryopyrin-Associated Periodic SyndromesFirst studyNCT05812781 · 7 enrolled · United States
  2. Feb 14, 2025Phase 2 study in PericarditisNCT06836232 · 50 planned · United States, Belgium, Canada and more

Ahead

  1. Oct 2027Primary completion: phase 2 study in PericarditisNCT06836232

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06836232Pericarditis · United States, Belgium, Canada and more2RecruitingOct 202750
NCT05812781Cryopyrin-Associated Periodic Syndromes · United States2CompletedMar 6, 20247

How it is read

Names in the registry

  • “VTX2735”, 7 entries

Codes read as this program: VTX2735.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.